- Home
- HBB vs CMPS Comparison
HBB vs CMPS Comparison
Compare HBB & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- CMPS
- Stock Information
- Founded
- HBB 1904
- CMPS 2020
- Country
- HBB United States
- CMPS United Kingdom
- Employees
- HBB N/A
- CMPS N/A
- Industry
- HBB Home Furnishings
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- HBB Consumer Discretionary
- CMPS Health Care
- Exchange
- HBB Nasdaq
- CMPS Nasdaq
- Market Cap
- HBB 292.6M
- CMPS 280.2M
- IPO Year
- HBB 2017
- CMPS 2020
- Fundamental
- Price
- HBB $16.21
- CMPS $4.03
- Analyst Decision
- HBB
- CMPS Strong Buy
- Analyst Count
- HBB 0
- CMPS 6
- Target Price
- HBB N/A
- CMPS $33.60
- AVG Volume (30 Days)
- HBB 54.3K
- CMPS 666.3K
- Earning Date
- HBB 10-30-2024
- CMPS 10-31-2024
- Dividend Yield
- HBB 2.81%
- CMPS N/A
- EPS Growth
- HBB 107.04
- CMPS N/A
- EPS
- HBB 1.88
- CMPS N/A
- Revenue
- HBB $647,834,000.00
- CMPS N/A
- Revenue This Year
- HBB $4.60
- CMPS N/A
- Revenue Next Year
- HBB N/A
- CMPS N/A
- P/E Ratio
- HBB $8.63
- CMPS N/A
- Revenue Growth
- HBB 5.30
- CMPS N/A
- 52 Week Low
- HBB $14.34
- CMPS $3.86
- 52 Week High
- HBB $31.78
- CMPS $12.75
- Technical
- Relative Strength Index (RSI)
- HBB 23.98
- CMPS 37.75
- Support Level
- HBB $16.12
- CMPS $3.86
- Resistance Level
- HBB $17.07
- CMPS $4.20
- Average True Range (ATR)
- HBB 0.93
- CMPS 0.29
- MACD
- HBB 0.04
- CMPS 0.00
- Stochastic Oscillator
- HBB 6.81
- CMPS 16.59
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.